Y

YSP Southeast Asia Holding Bhd
KLSE:YSPSAH

Watchlist Manager
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Watchlist
Price: 2.08 MYR Market Closed
Market Cap: 295m MYR

Relative Value

The Relative Value of one YSPSAH stock under the Base Case scenario is hidden MYR. Compared to the current market price of 2.08 MYR, YSP Southeast Asia Holding Bhd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

YSPSAH Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

YSPSAH Competitors Multiples
YSP Southeast Asia Holding Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
295m MYR 0.8 12.2 5.1 5.1
US
Eli Lilly and Co
NYSE:LLY
983.5B USD 16.6 53.7 36 38.6
US
Johnson & Johnson
NYSE:JNJ
546.4B USD 5.8 20.4 14.2 17.4
CH
Roche Holding AG
SIX:ROG
277.3B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210B GBP 4.9 30.2 19.7 28.8
CH
Novartis AG
SIX:NOVN
220.8B CHF 5 19.4 15.6 20.1
US
Merck & Co Inc
NYSE:MRK
273.5B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
149.1B USD 2.4 15.2 7.7 10.5
FR
Sanofi SA
PAR:SAN
96.4B EUR 1.4 7 6.4 6.4
P/E Multiple
Earnings Growth PEG
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average P/E: 21.8
12.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.4
14%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
27%
0.6
FR
Sanofi SA
PAR:SAN
7
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average EV/EBITDA: 43.9
5.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average EV/EBIT: 93.8
5.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.4
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
CH
Novartis AG
SIX:NOVN
20.1
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4